Adding flubendazole to standard treatment for high-grade glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial adds an investigational drug called flubendazole to the standard treatment (chemotherapy and radiation) for high-grade glioma. The goal is to see if adding this drug helps improve outcomes for people with this type of brain tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old.
- You must have a confirmed high-grade glioma (WHO grade 3 or 4) after surgery.
- You should be able to manage your daily activities (ECOG score 0-2).
- Your doctor must consider you fit for standard chemoradiation treatment.
- You cannot have another active cancer.
- You cannot be pregnant or breastfeeding, and you must not be allergic to flubendazole.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (flazoparib and temozolomide) given after the standard initial treatment for glioblastoma. The goal is to see if this combination is safe and effective in preventing the cancer from growing back.
This trial tests whether adding a drug called mycophenolate mofetil to the standard treatment (radiation therapy and temozolomide) helps people with a newly diagnosed brain cancer called glioblastoma. The drug may boost the effect of the standard treatment.
This trial tests a new experimental drug (FZ-AD005) for people with a fast-growing brain tumor called high-grade glioma. The drug is designed to target and attack cancer cells that have a specific protein (DLL3) on their surface, which may help stop the tumor from growing.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This study looks at how your immune system reacts to brain tumor surgery and standard treatment, using a special dye to help the surgeon see the tumor better. It aims to find out if this approach can improve outcomes for people with glioblastoma.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Glioma Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.